Vote Scores
Filings read through

Tango Therapeutics, Inc.: how funds voted at the meeting of 5 Jun 2025

Ticker
TNGX
Meeting
Season
year to 30 June 2025
Filers reporting
182
Ballot items
5

182 filers on Form N-PX reported votes at the Tango Therapeutics, Inc. meeting of 5 Jun 2025. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Tango Therapeutics, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2025. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    1 nominee. 50.9% of the reported votes are for. 35 filers withheld from or voted against at least one nominee.

    113 vote records from 63 filers. 33 of the 63 filers that marked the item voted against management.

    • Positions of 29 fund families
    • For 13
    • Abstain or withhold 16
    • Against management 16
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    253 vote records from 180 filers. 41 of the 173 filers that marked the item voted against management. 7 filers gave no management mark.

    • Positions of 36 fund families
    • For 27
    • Against 9
    • Against management 9
  3. Item 3: Frequency of the say-on-pay vote

    One year: 164 filers. For: 6 filers. Three years: 2 filers. Shares year 1: 1 filer. 1-year: 1 filer. Abstain: 1 filer.

    255 vote records from 181 filers. 3 of the 174 filers that marked the item voted against management. 7 filers gave no management mark.

    • Positions of 36 fund families
    • Split or no vote 36
    • Against management 1
  4. Item 4: Audit-related items (auditor ratification)

    113 vote records from 63 filers. 1 of the 63 filers that marked the item voted against management.

    • Positions of 29 fund families
    • For 29
  5. Item 5: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    113 vote records from 63 filers. 1 of the 63 filers that marked the item voted against management.

    • Positions of 29 fund families
    • For 29

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Tango Therapeutics, Inc., meeting of 5 Jun 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Pay-vote frequency4. Auditor
AllianceBernsteinForSplitNo report
American CenturyAgainst, against managementSplitFor
BlackRock and iSharesForSplitFor
BNY MellonForSplitNo report
Charles SchwabAgainst, against managementSplitFor
Columbia ThreadneedleForSplitFor
DimensionalAgainst, against managementSplit, against managementFor
DWSForSplitFor
EquitableForSplitFor
Federated HermesForSplitNo report
FidelityForSplitFor
Franklin TempletonForSplitFor
Global XAgainst, against managementSplitFor
Goldman SachsForSplitFor
Guggenheim and RydexForSplitFor
InvescoAgainst, against managementSplitFor
J.P. MorganAgainst, against managementSplitNo report
Jackson National fundsForSplitFor
John Hancock and ManulifeForSplitFor
Lincoln FinancialForSplitFor
MassMutualForSplitFor
Morgan Stanley, Eaton Vance and CalvertForSplitFor
NationwideForSplitFor
Northern Trust and FlexSharesForSplitFor
Nuveen and TIAAForSplitFor
Pacific Life fundsForSplitFor
PGIM and PrudentialAgainst, against managementSplitNo report
PrincipalForSplitNo report
ProShares and ProFundsForSplitFor
Russell InvestmentsAgainst, against managementSplitNo report
SEIAgainst, against managementSplitFor
State Street and SPDRForSplitFor
T. Rowe PriceForSplitFor
VanguardForSplitFor
Victory CapitalForSplitFor
VoyaForSplitFor

Questions

How many filers reported votes at the Tango Therapeutics, Inc. meeting?
182 Form N-PX filers reported votes at the meeting of 5 Jun 2025. On say-on-pay, 41 of 173 filers that marked the item voted against management (23.7%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Tango Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Tango Therapeutics, Inc. with a meeting date within three days of 5 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .